HOME ZACKS RESEARCH FUNDS PORTFOLIO BROKER RESEARCH MARKETS SCREENING VIDEO EDUCATION SERVICES
Zacks Rank    Equity Research    Premium Home    My Account    Help    
View All | Scroll Down Scroll Up
Quote:
Login Free Membership
Search:

Bear of the Day

Myriad Genetics (MYGN)

Share
By: Zacks Equity Research
November 16, 2009 |Comments: 0
Recommended this article (0)
MYGN

Myriad Genetics Inc. (MYGN) reported first quarter fiscal 2010 earnings of 31 cents per share, which was below the Zacks Consensus Estimate by a penny. The company had earned 25 cents per share in the year-ago period.

Myriad Genetics spun off its therapeutics business in July 2009 to focus on molecular diagnostics going forward. Although the molecular diagnostics business is performing well, we remain concerned about the slowdown in revenue growth in recent quarters.

The competition confronting Myriad Genetics products in the biotechnology and genetics testing field is also a concern. We have an Underperform rating on the stock.

Myriad Genetics (MYGN) : FULL ANALYST REPORT

Bear of the Day
Every day we feature one stock with a Zacks Recommendation of Sell that is set to underperform over the next 6+ months. We also provide you with free access to the in-depth research report on the stock. If you would like to see all our Buy and Sell rated stocks and in-depth research reports, then check out  Zacks Premium.

Read the full analyst report on MYGN

 
Add a Comment

Please login or register to post a comment

Email
Print
Share
Rate Pos
Rate Neg
Comment

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

More Zacks Links

Market Summary Feb 10, 2012 11:37 am ET
DJIA 12773.72  -116.74 -0.91%
NASD 2907.7  -19.53 -0.67%
S&P 500 1341.47  -10.48 -0.78%
Partner Center

Top Zacks Features

Free Membership
Zacks Rank
Equity Research
Portfolio Tracker
Screening
Profit Tracks
Mutual Funds
Options
Zacks Video
Education
RSS Feed
Profit from the Pros

Subscription Services

Product Guide
Method for Trading
Chart Patterns Trader
Insider Trader
Options Trader
Reitmeister Alert
Small Cap Trader
Turnaround Trader
Whisper Trader
Home Run Investor
Top 10 Stocks
Research Wizard
Zacks Premium
People & Picks
Zacks.com: About Zacks | Education | Advertise | Affiliate | Media | Careers | Contact Us | Services | Help | Disclaimer | Privacy Policy | Sitemap

Copyright 2011 Zacks Investment Research

Zacks Investment Research is one of the most highly regarded firms in the investment industry. The guiding principle behind our work is that there must be a good reason for brokerage firms to spend billions of dollars a year on stock research. Obviously, these investment experts know something special that may be indicative of the future direction of stock prices. From day one, we were determined to unlock that secret knowledge and make it available to our clients to help them improve their investment results.

NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.